Cargando…
Role of biomarkers in the management of antibiotic therapy: an expert panel review II: clinical use of biomarkers for initiation or discontinuation of antibiotic therapy
Biomarker-guided initiation of antibiotic therapy has been studied in four conditions: acute pancreatitis, lower respiratory tract infection (LRTI), meningitis, and sepsis in the ICU. In pancreatitis with suspected infected necrosis, initiating antibiotics best relies on fine-needle aspiration and d...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716933/ https://www.ncbi.nlm.nih.gov/pubmed/23830525 http://dx.doi.org/10.1186/2110-5820-3-21 |
_version_ | 1782277621971681280 |
---|---|
author | Quenot, Jean-Pierre Luyt, Charles-Edouard Roche, Nicolas Chalumeau, Martin Charles, Pierre-Emmanuel Claessens, Yann-Eric Lasocki, Sigismond Bedos, Jean-Pierre Péan, Yves Philippart, François Ruiz, Stéphanie Gras-Leguen, Christele Dupuy, Anne-Marie Pugin, Jérôme Stahl, Jean-Paul Misset, Benoit Gauzit, Rémy Brun-Buisson, Christian |
author_facet | Quenot, Jean-Pierre Luyt, Charles-Edouard Roche, Nicolas Chalumeau, Martin Charles, Pierre-Emmanuel Claessens, Yann-Eric Lasocki, Sigismond Bedos, Jean-Pierre Péan, Yves Philippart, François Ruiz, Stéphanie Gras-Leguen, Christele Dupuy, Anne-Marie Pugin, Jérôme Stahl, Jean-Paul Misset, Benoit Gauzit, Rémy Brun-Buisson, Christian |
author_sort | Quenot, Jean-Pierre |
collection | PubMed |
description | Biomarker-guided initiation of antibiotic therapy has been studied in four conditions: acute pancreatitis, lower respiratory tract infection (LRTI), meningitis, and sepsis in the ICU. In pancreatitis with suspected infected necrosis, initiating antibiotics best relies on fine-needle aspiration and demonstration of infected material. We suggest that PCT be measured to help predict infection; however, available data are insufficient to decide on initiating antibiotics based on PCT levels. In adult patients suspected of community-acquired LRTI, we suggest withholding antibiotic therapy when the serum PCT level is low (<0.25 ng/mL); in patients having nosocomial LRTI, data are insufficient to recommend initiating therapy based on a single PCT level or even repeated measurements. For children with suspected bacterial meningitis, we recommend using a decision rule as an aid to therapeutic decisions, such as the Bacterial Meningitis Score or the Meningitest®; a single PCT level ≥0.5 ng/mL also may be used, but false-negatives may occur. In adults with suspected bacterial meningitis, we suggest integrating serum PCT measurements in a clinical decision rule to help distinguish between viral and bacterial meningitis, using a 0.5 ng/mL threshold. For ICU patients suspected of community-acquired infection, we do not recommend using a threshold serum PCT value to help the decision to initiate antibiotic therapy; data are insufficient to recommend using PCT serum kinetics for the decision to initiate antibiotic therapy in patients suspected of ICU-acquired infection. In children, CRP can probably be used to help discontinue therapy, although the evidence is limited. In adults, antibiotic discontinuation can be based on an algorithm using repeated PCT measurements. In non-immunocompromised out- or in- patients treated for RTI, antibiotics can be discontinued if the PCT level at day 3 is < 0.25 ng/mL or has decreased by >80-90%, whether or not microbiological documentation has been obtained. For ICU patients who have nonbacteremic sepsis from a known site of infection, antibiotics can be stopped if the PCT level at day 3 is < 0.5 ng/mL or has decreased by >80% relative to the highest level recorded, irrespective of the severity of the infectious episode; in bacteremic patients, a minimal duration of therapy of 5 days is recommended. |
format | Online Article Text |
id | pubmed-3716933 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Springer |
record_format | MEDLINE/PubMed |
spelling | pubmed-37169332013-07-22 Role of biomarkers in the management of antibiotic therapy: an expert panel review II: clinical use of biomarkers for initiation or discontinuation of antibiotic therapy Quenot, Jean-Pierre Luyt, Charles-Edouard Roche, Nicolas Chalumeau, Martin Charles, Pierre-Emmanuel Claessens, Yann-Eric Lasocki, Sigismond Bedos, Jean-Pierre Péan, Yves Philippart, François Ruiz, Stéphanie Gras-Leguen, Christele Dupuy, Anne-Marie Pugin, Jérôme Stahl, Jean-Paul Misset, Benoit Gauzit, Rémy Brun-Buisson, Christian Ann Intensive Care Review Biomarker-guided initiation of antibiotic therapy has been studied in four conditions: acute pancreatitis, lower respiratory tract infection (LRTI), meningitis, and sepsis in the ICU. In pancreatitis with suspected infected necrosis, initiating antibiotics best relies on fine-needle aspiration and demonstration of infected material. We suggest that PCT be measured to help predict infection; however, available data are insufficient to decide on initiating antibiotics based on PCT levels. In adult patients suspected of community-acquired LRTI, we suggest withholding antibiotic therapy when the serum PCT level is low (<0.25 ng/mL); in patients having nosocomial LRTI, data are insufficient to recommend initiating therapy based on a single PCT level or even repeated measurements. For children with suspected bacterial meningitis, we recommend using a decision rule as an aid to therapeutic decisions, such as the Bacterial Meningitis Score or the Meningitest®; a single PCT level ≥0.5 ng/mL also may be used, but false-negatives may occur. In adults with suspected bacterial meningitis, we suggest integrating serum PCT measurements in a clinical decision rule to help distinguish between viral and bacterial meningitis, using a 0.5 ng/mL threshold. For ICU patients suspected of community-acquired infection, we do not recommend using a threshold serum PCT value to help the decision to initiate antibiotic therapy; data are insufficient to recommend using PCT serum kinetics for the decision to initiate antibiotic therapy in patients suspected of ICU-acquired infection. In children, CRP can probably be used to help discontinue therapy, although the evidence is limited. In adults, antibiotic discontinuation can be based on an algorithm using repeated PCT measurements. In non-immunocompromised out- or in- patients treated for RTI, antibiotics can be discontinued if the PCT level at day 3 is < 0.25 ng/mL or has decreased by >80-90%, whether or not microbiological documentation has been obtained. For ICU patients who have nonbacteremic sepsis from a known site of infection, antibiotics can be stopped if the PCT level at day 3 is < 0.5 ng/mL or has decreased by >80% relative to the highest level recorded, irrespective of the severity of the infectious episode; in bacteremic patients, a minimal duration of therapy of 5 days is recommended. Springer 2013-07-08 /pmc/articles/PMC3716933/ /pubmed/23830525 http://dx.doi.org/10.1186/2110-5820-3-21 Text en Copyright ©2013 Quenot et al.; licensee Springer. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Quenot, Jean-Pierre Luyt, Charles-Edouard Roche, Nicolas Chalumeau, Martin Charles, Pierre-Emmanuel Claessens, Yann-Eric Lasocki, Sigismond Bedos, Jean-Pierre Péan, Yves Philippart, François Ruiz, Stéphanie Gras-Leguen, Christele Dupuy, Anne-Marie Pugin, Jérôme Stahl, Jean-Paul Misset, Benoit Gauzit, Rémy Brun-Buisson, Christian Role of biomarkers in the management of antibiotic therapy: an expert panel review II: clinical use of biomarkers for initiation or discontinuation of antibiotic therapy |
title | Role of biomarkers in the management of antibiotic therapy: an expert panel review II: clinical use of biomarkers for initiation or discontinuation of antibiotic therapy |
title_full | Role of biomarkers in the management of antibiotic therapy: an expert panel review II: clinical use of biomarkers for initiation or discontinuation of antibiotic therapy |
title_fullStr | Role of biomarkers in the management of antibiotic therapy: an expert panel review II: clinical use of biomarkers for initiation or discontinuation of antibiotic therapy |
title_full_unstemmed | Role of biomarkers in the management of antibiotic therapy: an expert panel review II: clinical use of biomarkers for initiation or discontinuation of antibiotic therapy |
title_short | Role of biomarkers in the management of antibiotic therapy: an expert panel review II: clinical use of biomarkers for initiation or discontinuation of antibiotic therapy |
title_sort | role of biomarkers in the management of antibiotic therapy: an expert panel review ii: clinical use of biomarkers for initiation or discontinuation of antibiotic therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716933/ https://www.ncbi.nlm.nih.gov/pubmed/23830525 http://dx.doi.org/10.1186/2110-5820-3-21 |
work_keys_str_mv | AT quenotjeanpierre roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy AT luytcharlesedouard roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy AT rochenicolas roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy AT chalumeaumartin roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy AT charlespierreemmanuel roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy AT claessensyanneric roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy AT lasockisigismond roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy AT bedosjeanpierre roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy AT peanyves roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy AT philippartfrancois roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy AT ruizstephanie roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy AT grasleguenchristele roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy AT dupuyannemarie roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy AT puginjerome roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy AT stahljeanpaul roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy AT missetbenoit roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy AT gauzitremy roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy AT brunbuissonchristian roleofbiomarkersinthemanagementofantibiotictherapyanexpertpanelreviewiiclinicaluseofbiomarkersforinitiationordiscontinuationofantibiotictherapy |